Novel Cox-2 Inhibitor for Breast Cancer Therapy
Abstract
Recent studies have shown that NSAIDS reduce the incidence of human cancers by inhibiting the COX enzymes. Of these, the inducible COX-2 isoform has been shown to be constitutively over-expressed in many tumor types, including those of the breast. The purpose of this study is to develop novel COX-2 inhibitors that can be used in breast cancer therapy. We developed seven classes of novel COX-2 inhibitors that possess tumor growth inhibitory activity. Some of these compounds inhibit the growth of both COX-2 positive and negative tumor cell lines, suggesting that they may target other protein(s) that play an important role in tumor cell proliferation. We have also determined that our most potent COX-2 inhibitor, which is nearly 6-fold more active than Celecoxib, induced irreversible G(sub 1) arrest of tumor cells and ultimately leads to tumor cell apoptosis. These studies suggest that these compounds may have an important role as anti-cancer agents.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2004
- Accession Number
- ADA431390
Entities
People
- E. Premkumar Reddy
Organizations
- Temple University